News Summary: Royalty Pharma lets Elan bid expire

Published



TAKEOVER UPDATE: Royalty Pharma said Tuesday it has let its latest takeover bid for Irish drugmaker Elan lapse as it decided against pressing ahead with a court challenge of a requirement that it withdraw the offer.

THE DETAILS: Royalty had offered earlier this month to pay $13 per share for each Elan share plus up to $2.50 per share in payments based on performance milestones.

Trusted reporting.Unlimited access.

Subscribe for full access to Washington Examiner coverage, expert political analysis, and subscriber-only journalism.

Get Unlimited Access

Already a member? Log in

Cancel anytime.